211 At and 125 I-Labeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again

Chemistry. 2022 Feb 19;28(11):e202104169. doi: 10.1002/chem.202104169. Epub 2022 Jan 28.

Abstract

Despite the growing interest in radioiodine and 211 At-labeled radiopharmaceuticals, the search for radiolabeling reactions has been somewhat neglected, resulting in a limited number of available radiosynthetic strategies. Herein we report a comparative study of nucleophilic 125 I and 211 At-labeling of aryliodonium ylides. Whereas radioiodination efficiency was low, 211 At-labeling performed efficiently on a broad scope of precursors. The most activated aryliodonium ylides led rapidly to quantitative reactions at room temperature in acetonitrile. For deactivated precursors, heating up to 90 °C in glyme and addition of 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) as radical scavenger appeared essential to avoid precursor degradation and to achieve high radiochemical yields and molar activity. The approach was applied successfully to the preparation of 4-[211 At]astatophenylalanine (4-APA), an amino acid derivative increasingly studied as radiotherapeutic drug for cancers. This validated aryliodonium ylides as a valuable tool for nucleophilic 211 At-labeling and will complement the short but now growing list of available astatination reactions.

Keywords: astatine-211; halogenation; iodine-125; iodonium ylides; radiolabeling.

MeSH terms

  • Astatine* / chemistry
  • Iodine Radioisotopes / chemistry
  • Pharmaceutical Preparations*
  • Radiopharmaceuticals / chemistry

Substances

  • Iodine Radioisotopes
  • Pharmaceutical Preparations
  • Radiopharmaceuticals
  • Astatine